Evidence map›Paper›PMID 38533909›Full record

ArticleJournal of proteome research2024

Use of Nonhuman Sera as a Highly Cost-Effective Internal Standard for Quantitation of Multiple Human Proteins Using Species-Specific Tryptic Peptides: Applicability in Clinical LC-MS Analyses.

Geraldine Williams, Lewis Couchman, David R Taylor, Jatinderpal K Sandhu, Oliver C Slingsby, Leong L Ng, Cajetan F Moniz, Donald J L Jones, Colleen B Maxwell

Abstract read
In one paragraph

Article in Journal of proteome research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Geraldine WilliamsLeicester van Geest MS-OMICS Facility, Hodgkin Building, University of Leicester, Leicester LE1 9HN, United Kingdom.
Lewis CouchmanLeicester Cancer Research Centre, RKCSB, University of Leicester, Leicester LE2 7LX, United Kingdom.ORCID 0000-0002-0464-7886
David R TaylorViapath Analytics, King's College Hospital, Denmark Hill, London SE5 9RS, United Kingdom.
Jatinderpal K SandhuLeicester van Geest MS-OMICS Facility, Hodgkin Building, University of Leicester, Leicester LE1 9HN, United Kingdom.
Oliver C SlingsbyLeicester van Geest MS-OMICS Facility, Hodgkin Building, University of Leicester, Leicester LE1 9HN, United Kingdom.ORCID 0000-0002-3355-5163
Leong L NgLeicester van Geest MS-OMICS Facility, Hodgkin Building, University of Leicester, Leicester LE1 9HN, United Kingdom.
Cajetan F MonizDepartment of Clinical Biochemistry, King's College Hospital, Denmark Hill, London SE5 9RS, United Kingdom.
Donald J L JonesLeicester van Geest MS-OMICS Facility, Hodgkin Building, University of Leicester, Leicester LE1 9HN, United Kingdom.ORCID 0000-0001-6583-870X
Colleen B MaxwellLeicester van Geest MS-OMICS Facility, Hodgkin Building, University of Leicester, Leicester LE1 9HN, United Kingdom.ORCID 0000-0003-4463-3566

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Quantitation of proteins using liquid chromatography-tandem mass spectrometry (LC-MS/MS) is complex, with a multiplicity of options ranging from label-free techniques to chemically and metabolically labeling proteins. Increasingly, for clinically relevant analyses, stable isotope-labeled (SIL) internal standards (ISs) represent the "gold standard" for quantitation due to their similar physiochemical properties to the analyte, wide availability, and ability to multiplex to several peptides. However, the purchase of SIL-ISs is a resource-intensive step in terms of cost and time, particularly for screening putative biomarker panels of hundreds of proteins. We demonstrate an alternative strategy utilizing nonhuman sera as the IS for quantitation of multiple human proteins. We demonstrate the effectiveness of this strategy using two high abundance clinically relevant analytes, vitamin D binding protein [Gc globulin] (DBP) and albumin (ALB). We extend this to three putative risk markers for cardiovascular disease: plasma protease C1 inhibitor (SERPING1), annexin A1 (ANXA1), and protein kinase, DNA-activated catalytic subunit (PRKDC). The results show highly specific, reproducible, and linear measurement of the proteins of interest with comparable precision and accuracy to the gold standard SIL-IS technique. This approach may not be applicable to every protein, but for many proteins it can offer a cost-effective solution to LC-MS/MS protein quantitation.

Indexed as

Liquid Chromatography-Mass SpectrometryTandem Mass SpectrometryAnimalsBiomarkersCost-Benefit AnalysisHumansIsotope LabelingPeptidesProteomicsReference StandardsReproducibility of ResultsSerum AlbuminTrypsinVitamin D-Binding ProteinBiomarkersPeptidesSerum AlbuminTrypsinVitamin D-Binding Proteinbottom-up proteomicscardiovascular risk markerslow costmultiple reaction monitoringquantitationquantitative proteomicsselected reaction monitoringsurrogate standardtargeted proteomics

Identifiers

PMID38533909
PMCPMC11301776

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.